- Intellectual Property (38)
- Healthcare (18)
- Company/Commercial (15)
- Litigation / Dispute Resolution (13)
- Information Technology (12)
- Corporate (8)
- Regulatory and compliance (7)
- Banking / Finance (6)
- Media/Entertainment/Sport (6)
- Funds (5)
- Telecoms (4)
- Employment (3)
- Licensing/Gaming/Betting (3)
- Competition/EU (2)
- Insolvency & restructuring (2)
- Real Estate (2)
- Tax (2)
- Construction (1)
- Energy (1)
- Environment (1)
- Financial services (1)
- Planning (1)
- Private Client (1)
- Transport (Including aviation and shipping) (1)
Sort By: Newest first | Oldest first
Fundraisings of early-stage life science companies can be complicated affairs from the point of view of actually securing the funds from investors in the first place.
The articles of association are a contract between the company and each shareholder and between the shareholders themselves.
A life sciences company raises funds either by issuing shares or by borrowing money from individuals, venture capital bodies or lending institutions.
Two new references have been made to the CJEU asking for preliminary rulings on issues under Regulation (EC) No 469/2009.
A number of life sciences industry bodies have jointly published a report entitled ‘From vision to action: delivery of the strategy for UK life sciences’.
It is common in investments for life sciences companies for a term sheet to be put in place between the investors and the founders that sets out the key terms of the investment.
This case relates to an application for payment of damages, further to a cross-undertaking on a preliminary injunction.
One innovative deal structure is geographical licensing. While apparently simple on the face of it, the devil is in the detail.
The latter half of 2013 proved to be an interesting period for the pharmaceutical sector from a competition law perspective.
Taylor Wessing has launched its third Cambridge newsletter, providing legal news and updates for companies in Cambridge and the surrounding areas.
After four years of waiting, the Food and Drug Administration has released its draft social media guidance.
The first preliminary injunction decision in Germany relating to a ‘bio-better’ type drug has been made in Amgen v Teva in the Düsseldorf District Court.
This unusual application related to proceedings to revoke a European patent and a declaration that an SPC based upon it would not be valid.
The CJEU delivered three important rulings on the application of the supplementary protection certificate regulation 469/2009/EC on the same day.
In the life sciences industry, highly skilled people are employed in the research and development of drug candidates and other advancements associated with therapy.
A Düsseldorf court has referred questions to the CJEU on the supply of substances by a third party to a company that intends to use the substance for obtaining a marketing authorisation.
On 9 December 2013, the European Commission published its report on the monitoring of patent settlements from January to December 2012.
Taylor Wessing’s lawyers from Austria, Germany and the UK explain their respective national approaches to the issue of ex-employees in possession of trade secrets.
CJEU referral of the Düsseldorf Court of Appeal regarding third-party supply for Bolar exemption purposes
A Düsseldorf court has referred questions to the CJEU on whether the supply of patent-protected substances by a third party to a generic company is covered by the Bolar exemption.
On 5 December 2013, the Court of Justice of the European Union published its decision on the appeal of the European Medicines Agency.